Sodium butyrate do not induce the program of premature senescence in transformants with jnk1,2 knockout

Tsitologiya

Volumn 50, Issue 11, 2008, Pages 964-971

  Zubova, S G ^a   Bykova, T V ^a   Zubova, J G ^a   Romanov, V S ^a   Aksenov, N D ^a   Pospelov, V A ^a   Pospelova, T V ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

2 kinase; Cell cycle; JNK1; Oncogenes E1A and cHa ras; Senescence; Sodium butyrate; Transformation

Indexed keywords

BETA GALACTOSIDASE; BUTYRIC ACID DERIVATIVE; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, MOUSE; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE 9; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL; ANIMAL EMBRYO; ARTICLE; CELL AGING; CELL LINE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; FIBROBLAST; GENETIC TRANSFORMATION; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; ONCOGENE RAS; PHYSIOLOGY;

ANIMALS; BETA-GALACTOSIDASE; BUTYRATES; CELL AGING; CELL LINE, TRANSFORMED; CELL PROLIFERATION; E1A-ASSOCIATED P300 PROTEIN; EMBRYO, MAMMALIAN; FIBROBLASTS; GENES, RAS; HISTONE DEACETYLASES; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; TRANSFORMATION, GENETIC;

EID: 59449095896     PISSN: 00413771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. 1/S arrest induced by histone deacetylase inhibitor sodium butyrate in Ela + Ras transformed cells is mediated through down-regulation of E2F activity and stabilization of beta catenin. J. Biol. Chem. 28 : 21 040-21 051.
9. Behrens A., Jochum W., Sibiilia M., Wagner E. F. 2000. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphoiylation. Oncogene. 19 : 2657-2663.
10. Benanti J. A., Galloway D. A. 2004. The normal response to RAS: senescence or transformation? Cell Cycle. 3 : 715-717.
11. Blagosklonny M. V. 2006. Cell senescence: hypertrophic arrest beyond the restriction point. J. Cell. Physiol. 209 : 592-597.
12. Bost F., McKay R., Bost M., Potapova O., Dean N. M., Mercola D. 1999. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol. 19 : 1936-1949.
13. Brichkina A., Angel P., Pospelova T., Herrlich P. 2006. Activation of JNK/cJun by adenoviral El A oncoprotein. FEBS-EMBO Advanced Lecture Cours: Molecular Mechanisms in Signal Transduction and Cancer. Island of Spetses, Greece.
14. Bulavin D. V., Pospelov V. A., Pospelova T. V. 1999. Oncoprotein El Aad5 interact with universal inhibitor of cyclin-dependent kinases p21/waf-l and inhibit its activity in E1A + cHa-ras trans-formants. Mol. Biol. (Moscow). 33 (4) : 641-643.
15. Campisi J. 2005. Aging, tumor suppression and cancer: high wire-act! Mech. Aging Develop. 126 : 51-58.
16. Chang B. D., Broude E. V., Dokmanovic M, Zhu H., Ruth A., XuanY., Kandel E. S., Lausch E., Christov K., Roninson I. B. 1999a. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59 : 3761-3767.
17. Chang B.D., Xuan Y., BroudeE. V., ZhuH., Schott B., Fang J., Roninson I. B. 1999b. Role of p53 and p21wafl/cipl in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 18:4808-4818.
18. Collado M., Blasco M. A., Serrano M. 2007. Cellular senescence in cancer and aging. Cell. 130 : 223-233.
19. Collado M., Serrano M. 2005. The senescent side of tumor suppression. Cell Cycle. 4 : 1722-1724.
20. Das M., Jiang F., Sluss H. K., Zhang C., Shokat K. M., Flavel R.A., Davis R. J. 2007. Suppression of p53-dependent senes-cence by the JNK signal transduction pathway. PNAS. 104 : 15 759-15 764.
21. Davenport E. A., Taparowsky E. J. 1990. Novel phenotype of C3H 10T1/2 fibroblasts cotransfected with the c-Ha-ras and adenovirus 5 E1A oncogenes. Mol. Carcinog. 3 : 83-92.
22. Davis R. J. 2000. Signal transduction by the JNK group of MAP kinases. Cell. 103 : 239-252.
23. Dimri G. P., Lee X., Basile G., Acosta M, Scott G., Roskelley C., Medrano E. E., Linskens M., Rubelj I., Pereira-Smith O., Peacocke M., Campisi J. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Nat. Acad. Sci. USA. 92 : 9363-9367.
24. Fuchs S.Y., Adler V., Pincus M. R., Ronai Z, 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc. Nat. Acad. Sci. USA. 95 : 10 541-10 546.
25. Garay M., Gaarde W., Mania B. P., Nero P., Cioffi C. L. 2000. Inhibition of hypoxia/reoxygenation-induced apoptosis by an antisense oligonucleotide targeted to JNK1 in human kidney cells. Biochem. Pharmacol. 59 : 1033-1043.
26. Heasley L. E., Han S.-Y. 2006. JNK regulation of oncogenesis. Mol. Cells. 21 : 167-173.
27. Ho F. M., Liu S. H., Liau C. S., Huang P. J., Lin-Shiau S. Y. 2000. High glucose-induced apoptosis in human endothelial cells is mediated by sequetial activation of c-jun NH2-terminal kinase and caspase-3. Circulation. 101 : 2618-2624.
28. Kang S., Jung M., Kim C.-W., Shin D. 2005. Inactivation of p38 kinase delays the onset of senescence in rabbit articular chondrocytes. Mech. Aging Develop. 126 : 591-597.
29. Kennedy N. J., Sluss H. K., Jones S. N., Bar-Sagi D., Flavell R. A., Davis R. J. 2003. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Develop. 17 : 629-637.
30. Kukushkin A. N., Abramova M. V., Svetlikova S. B., Darieva Z. A., Pospelova T. V., Pospelov V. A. 2002. Downregulation of c-fos gene transcription in cells transformed by El A and cHa-ras oncogenes: a role of sustained activation of MAP/Erk kinase cascade and of inactive chromatin structure at c-fos promoter. Oncogene. 21 : 719-730.
31. 2/M transition by triggering the p38 MAPK checkpoint pathway. J. Cell Biol. 166 : 517-526.
32. Pospelova T. V., Medvedev A. N., Kukushkin A. N., Svetlikova S.B., van der Eb A. J., Dorsman J. C., Pospelov V. A. 1999. E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. Gene Exp. 8 : 19-32.
33. Potapova O., Gorospe M., Dougherty R. H., Dean N. M, Gaarde W. A., Holbrook N. J. 2000. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol. Cell. Biol. 20 : 1713-1722.
34. Pulverer B. J., Kyriakis J. M., Avruch J., Nikolakaki E., Woodgett J. R. 1991. Phosphorylation of c-jun mediated by MAP kinases. Nature. 353 : 670-674.
35. Roninson I. B. 2003. Tumor cell senescence in cancer treatment. Cancer Res. 63 : 2705-2715.
36. Shapiro H. M. 1988. Practical flow cytometry. New York: Alan R. Liss., Inc. 353 p.
37. Shields J. M, Pruitt K., McFall A., Shaub A., Der C. J. 2000. Understanding Ras: «in ain't over 'til it's over». Trends Cell Biol. 10 : 147-154.
38. Wada T., Stepniak E., Hui L., Leibbrandt A., Katada T., Nishina H., Wagner E. F., Penninger J. M. 2007. Antagonistic control of cell fates by JNK and p38-MAPK signaling. Cell Death Different. 1-5.
39. Winn R. A., Marek L., Han S. Y., Rodriguez K., Rodriguez N. 2005. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J. Biol. Chem. 280 : 19 635-19 634.
40. Yamada S. D., Hickson J.A., Hrobowski Y., Vander Griend D. J., Benson D., Montag A., Karrison T., Huo D., Rutgers J., Adams S. 2002. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res. 62 : 6717-6723.
41. Yoshida S., Fukino K., Harada H, Nagai H., Imoto I., Inazawa I., Takahashi H., Teramoto A., Emi M. 2001. The c-Jun NH2-terminal kinase 3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J. Hum. Genet. 46 : 182-186.